S
S. Corm
Researcher at Lille University of Science and Technology
Publications - 2
Citations - 547
S. Corm is an academic researcher from Lille University of Science and Technology. The author has contributed to research in topics: Chronic myelogenous leukemia & Dasatinib. The author has an hindex of 2, co-authored 2 publications receiving 531 citations.
Papers
More filters
Journal ArticleDOI
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Andreas Hochhaus,Michele Baccarani,Michael W. Deininger,Jane F. Apperley,Jeffrey H. Lipton,Stuart L. Goldberg,S. Corm,Neil P. Shah,Francisco Cervantes,Richard T. Silver,Dietger Niederwieser,Richard Stone,Hervé Dombret,Richard A. Larson,Lydia Roy,Timothy P. Hughes,Martin C. Müller,Rana Ezzeddine,A. Countouriotis,Hagop M. Kantarjian +19 more
TL;DR: Dasatinib is associated with high response rates in patients with imatinib-resistant or -intolerant CP-CML, and it is shown that this drug is effective for patients with chronic myelogenous leukemia resistant or intolerant toImatinib.
Journal ArticleDOI
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
Jorge E. Cortes,Dahye Kim,Emmanuel Raffoux,Giovanni Martinelli,Ellen K. Ritchie,Lydia Roy,Steven Coutre,S. Corm,Nelson Hamerschlak,Jih-Luh Tang,Andreas Hochhaus,Hanna Jean Khoury,Tim H. Brümmendorf,Mauricette Michallet,Giovanna Rege-Cambrin,Carlo Gambacorti-Passerini,Jerry Radich,Thomas Ernst,Chao Zhu,J. M.A. Van Tornout,Moshe Talpaz +20 more
TL;DR: Dasatinib is associated with a promising rate of response in this high-risk population of patients and had acceptable tolerability with dose interruptions/reductions.